Latest Breaking News On - Head of the infectious diseases department - Page 1 : comparemela.com

KSA Business: Saudi health expert Hanan Balkhi named WHO Mideast head

The World Health Organisation (WHO) has appointed leading Saudi

Al qahirahSaudi arabiaAl jalajelHanan balkhiHead of the infectious diseases departmentWorld health organisationTradearabia news serviceCase western reserve universityPartnership awardInternational researcher awardHead of the department infectious diseasesEastern mediterranean officeKing abdulaziz universityKing abdulaziz medical centerKing abdullah international medical research centerScientific research award

Saudi health expert Hanan Balkhi named WHO Mideast head

The World Health Organisation has appointed Saudi public health expert Dr Hanan Balkhi as the new regional director of its Eastern Mediterranean Office. A Saudi scientist, Balkhi has international expertise in her field with over 25 years of experience.

Saudi arabiaAl qahirahAr riyaAl jalajelHanan balkhiTradearabia news serviceHead of the infectious diseases departmentKing abdulaziz universityKing abdullah international medical research centerKing abdulaziz medical centerCase western reserve universitySaudi healthHead of the department infectious diseasesScientific research awardInternational researcher awardEastern mediterranean office

United Nations Report: Kuwait s Remarkable Progress in AIDS Control

United Nations Report: Kuwait s Remarkable Progress in AIDS Control
arabtimesonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from arabtimesonline.com Daily Mail and Mail on Sunday newspapers.

Osama al baksamiAl munther hasawiJamal al duaijHead of the infectious diseases departmentHealth ministry assistant undersecretaryNational committeeUnited nationsAl jahra health districtMiddle easternInfectious diseases hospitalInfectious diseases department

Gilead Sciences, Inc : Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program

Gilead Sciences, Inc : Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South africaUnited kingdomFrance generalUnited statesIhre chancenJean michel molinaIndiens wirtschaftMeaghan smithJacquie rossGilead sciencesGilead sciences incExchange commissionClinical developmentHead of the infectious diseases departmentGilead public affairsParis cit

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program - Gilead Sciences (NASDAQ:GILD)

– PURPOSE 5 trial will evaluate lenacapavir as twice-yearly prevention option in people who could benefit from HIV pre-exposure prophylaxis (PrEP) in France and the United Kingdom – Gilead Sciences, Inc. (NASDAQ:GILD)

France generalUnited statesUnited kingdomSouth africaJean michel molinaHead of the infectious diseases departmentGilead sciences incGilead sciencesClinical developmentExchange commissionParis citInfectious diseasesInfectious diseases departmentJared baetenVice presidentImportant safety information